MergerMay 5, 2026, 09:12 AM
Assertio, Garda Postpone Tender Offer Commencement to May 8
AI Summary
Assertio Holdings, Inc. and Garda Therapeutics, Inc. have mutually agreed to postpone the commencement of the previously announced tender offer for Assertio's outstanding shares to May 8, 2026. This postponement is in connection with the amended and restated merger agreement, under which Garda will acquire Assertio for $21.80 per share in cash, totaling $153.2 million. The tender offer for Assertio's Convertible Senior Notes will also be postponed until May 8, 2026, with a Schedule 14D-9 expected to be filed on the same date.
Key Highlights
- Assertio and Garda mutually agreed to postpone the commencement of the tender offer.
- The new deadline to commence the tender offer is May 8, 2026.
- Garda Therapeutics will acquire Assertio for $21.80 per share in cash.
- The total cash consideration for the acquisition is $153.2 million.
- The tender offer for Assertio's outstanding Convertible Senior Notes is also postponed to May 8, 2026.
- Assertio expects to file a Schedule 14D-9 in connection with the tender offer on May 8, 2026.